Candriam SCA’s Crescent Biopharma CBIO Stock Holding History

Candriam SCA’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-969	Closed	-$418K	–	796
2019 Q3	$418K	Hold	969	–	–	0.01%	699
2019 Q2	$1.15M	Buy	969 +235	+32%	+$281K	0.01%	627
2019 Q1	$915K	Buy	+734	New	+$840K	0.01%	649
2017 Q2	–	Sell	-1,600	Closed	-$869K	–	710
2017 Q1	$869K	Hold	1,600	–	–	0.02%	585
2016 Q4	$976K	Hold	1,600	–	–	0.02%	519
2016 Q3	$1.14M	Hold	1,600	–	–	0.03%	470
2016 Q2	$1.16M	Sell	1,600 -499	-24%	-$344K	0.03%	409
2016 Q1	$1.24M	Sell	2,099 -101	-5%	-$51.8K	0.03%	395
2015 Q4	$1.26M	Hold	2,200	–	–	0.03%	361
2015 Q3	$1.23M	Sell	2,200 -150	-6%	-$108K	0.03%	411
2015 Q2	$1.87M	Hold	2,350	–	–	0.04%	373
2015 Q1	$1.96M	Hold	2,350	–	–	0.04%	390
2014 Q4	$1.69M	Buy	+2,350	New	+$1.84M	0.04%	378

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Candriam SCA's CBIO Position: Q4 2019 in Review

Candriam SCA sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 969 shares — an estimated $418K sold.

Candriam SCA first reported a position in CBIO in Q4 2014 and held it in 13 quarters. The position peaked at $1.96M in Q1 2015. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

Candriam SCA reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
Candriam SCA sold 969 Crescent Biopharma shares in Q4 2019, an estimated $418K.
Candriam SCA first reported a position in Crescent Biopharma in Q4 2014 and held it in 13 quarters.
Candriam SCA's Crescent Biopharma position peaked at $1.96M in Q1 2015.
78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.